Unicycive Therapeutics In... (UNCY)
0.58
-0.03 (-5.54%)
At close: Mar 31, 2025, 12:58 PM
-5.54% (1D)
| Bid | 0.57 |
| Market Cap | 60.2M |
| Revenue (ttm) | -316.25K |
| Net Income (ttm) | -33.76M |
| EPS (ttm) | -0.46 |
| PE Ratio (ttm) | -1.26 |
| Forward PE | -1.54 |
| Analyst | Buy |
| Ask | 0.59 |
| Volume | 737,194 |
| Avg. Volume (20D) | 971,605 |
| Open | 0.62 |
| Previous Close | 0.61 |
| Day's Range | 0.57 - 0.62 |
| 52-Week Range | 0.20 - 1.60 |
| Beta | 2.25 |
About UNCY
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 12, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol UNCY
Website https://www.unicycive.com
Analyst Forecast
According to 3 analyst ratings, the average rating for UNCY stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 589.66% from the latest price.
Stock Forecasts5 months ago
+20.24%
Unicycive Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
9 months ago
-26.76%
Unicycive Therapeutics shares are trading lower. The company announced results from the Oxylanthanum Carbonate UNI-OLC-201 pivotal clinical trial.
